Spero Therapeutics
SPRO
94 hedge funds and large institutions have $273M invested in Spero Therapeutics in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 8 closing their positions.
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
6% more funds holding
Funds holding: 89 → 94 (+5)
4% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 26
7.31% less ownership
Funds ownership: 70.19% → 62.88% (-7.3%)
26% less capital invested
Capital invested by funds: $370M → $273M (-$97M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
44% less call options, than puts
Call options by funds: $889K | Put options by funds: $1.58M
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$17.9M |
| 2 |
Goldman Sachs
New York
|
+$3.77M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.98M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.62M |
| 5 |
Citigroup
New York
|
+$1.42M |
Top Sellers
SPRO Hedge Fund Activity: Q1 2021 in Review
94 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2021, worth a combined $273M — down 26% from $370M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new SPRO positions and 8 closed out — a net gain of 7 holders — while 27 added to existing stakes and 26 trimmed.
The largest buyer was State Street, adding an estimated $17.9M. The largest seller was Rock Springs Capital Management, cutting an estimated $4.74M.
- 94 institutional investors held Spero Therapeutics (SPRO) as of Q1 2021, up from 89 in Q4 2020.
- Funds reported $273M of Spero Therapeutics stock for Q1 2021, down 26% quarter-over-quarter.
- 15 funds opened new Spero Therapeutics positions in Q1 2021 and 8 closed out, a net change of +7 holders.
- The largest Spero Therapeutics buyer in Q1 2021 was State Street, an estimated $17.9M added.
- The largest Spero Therapeutics seller in Q1 2021 was Rock Springs Capital Management, an estimated $4.74M sold.
Based on aggregated 13F filings for Q1 2021.